Study of Acute Normovolemic Hemodilution with Goal-Directed Fluid Therapy in Adults Undergoing Bone Tumor Surgery

What this Trial Is About

Bone tumor surgery often leads to significant blood loss, which can cause postoperative anemia and increase the risk of complications and affect long-term survival. Researchers are evaluating the effect of acute normovolemic hemodilution ANH combined with goal-directed fluid therapy GDFT in patients undergoing bone tumor surgery. This study aims to determine if ANH can improve hemoglobin levels after surgery, addressing previous uncertainties about ANHs clinical benefits when fluid management is carefully controlled. Participants are randomly assigned to one of two groups. In the ANH group, blood is drawn after anesthesia and replaced with a fluid to maintain blood volume, followed by GDFT during surgery. In the standard care group, only GDFT is applied throughout the surgery without ANH. The trial carefully monitors fluid management strategies to assess the impact of ANH on patient outcomes. Throughout the study, participants will have their hemoglobin levels measured on the first day after surgery as the primary outcome. Secondary measures include blood loss, blood transfusion rates, fluid volume during surgery, coagulation tests, and infections up to seven days post-surgery. The study includes preoperative assessments, intraoperative monitoring, and postoperative follow-up to evaluate safety and efficacy over the hospital stay period.

A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery